State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China.
Int J Mol Sci. 2021 Oct 14;22(20):11078. doi: 10.3390/ijms222011078.
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection; the pathophysiology of sepsis is complex. The incidence of sepsis is steadily increasing, with worldwide mortality ranging between 30% and 50%. Current treatment approaches mainly rely on the timely and appropriate administration of antimicrobials and supportive therapies, but the search for pharmacotherapies modulating the host response has been unsuccessful. Chinese herbal medicines, i.e., Chinese patent medicines, Chinese herbal prescriptions, and single Chinese herbs, play an important role in the treatment of sepsis through multicomponent, multipathway, and multitargeting abilities and have been officially recommended for the management of COVID-19. Chinese herbal medicines have therapeutic actions promising for the treatment of sepsis; basic scientific research on these medicines is increasing. However, the material bases of most Chinese herbal medicines and their underlying mechanisms of action have not yet been fully elucidated. This review summarizes the current studies of Chinese herbal medicines used for the treatment of sepsis in terms of clinical efficacy and safety, pharmacological activity, phytochemistry, bioactive constituents, mechanisms of action, and pharmacokinetics, to provide an important foundation for clarifying the pathogenesis of sepsis and developing novel antisepsis drugs based on Chinese herbal medicines.
脓毒症是一种危及生命的器官功能障碍,由宿主对感染的失调反应引起;脓毒症的病理生理学非常复杂。脓毒症的发病率稳步上升,全球死亡率在 30%至 50%之间。目前的治疗方法主要依赖于及时和适当的使用抗生素和支持性治疗,但寻找调节宿主反应的药物治疗方法一直没有成功。中药,即中药成药、中药方剂和单味中药,通过多成分、多途径和多靶点的作用,在脓毒症的治疗中发挥着重要作用,并已被正式推荐用于 COVID-19 的治疗。中药在治疗脓毒症方面具有有前景的治疗作用;针对这些药物的基础科学研究正在增加。然而,大多数中药的物质基础及其作用机制尚未完全阐明。本综述从临床疗效和安全性、药理活性、植物化学、生物活性成分、作用机制和药代动力学等方面总结了用于治疗脓毒症的中药的研究现状,为阐明脓毒症的发病机制和开发基于中药的新型抗脓毒症药物提供了重要基础。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020-5-25
J Ethnopharmacol. 2021-4-24
Cochrane Database Syst Rev. 2013-8-28
Zhongguo Zhong Yao Za Zhi. 2021-1
Cochrane Database Syst Rev. 2012-11-14
Int J Mol Sci. 2023-11-21
Front Pharmacol. 2021-4-15